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Since 1980s non-selective beta-blockers (NSBBs) have 
become the cornerstone of medical treatment for portal 
hypertension in cirrhotic patients (1). Yet, the evidence 
for their efficacy to prevent variceal bleeding is derived 
from prospective trials which largely excluded patients 
with refractory ascites and renal failure that are patients 
in which the use of beta-blockers is nowadays under 
debate (2). In 2010, a prospective observational study, 
from the same group that had previously supported the 
use of NSBBs therapy in cirrhosis, suggested that these 
drugs might increase mortality in patients with refractory 
ascites. The authors investigated 151 cirrhotic patients 
with refractory ascites, 51% were taking propranolol for 
esophageal varices (it is not specified whether for primary 
or secondary prophylaxis), while 49% were not under 
propranolol treatment. They reported a median survival 
of 5 months in patients on propranolol versus 20 months 
in those not receiving this drug and gave a warning about 
the use of NSBBs in cirrhotic patients with refractory 
ascites (3). The study was, however, criticized both due to 
the high mean dosage of NSBBs and due to some relevant 
differences between the two groups of patients which 
might have influenced the results. To further investigate 
their hypothesis, the same authors performed a small 
crossover study aimed at evaluating the effect of NSBBs 
on the development of paracentesis-induced circulatory 
dysfunction (PICD). In this study, ten cirrhotic patients 
with refractory ascites taking NSBBs were enrolled and 
monitored before, immediately after and 1 week later after 
a large volume paracentesis. NSBBs were then discontinued 
(following endoscopic variceal treatment) and a further 
paracentesis was repeated followed by the same clinical 
evaluations. The incidence of PICD decreased from 80% 
to 10%, suggesting that NSBBs could have a potentially 
deleterious effect through further compromising the 
already impaired hemodynamic balance in patients with 
advanced cirrhosis and ascites (4). Additional studies were 
published in recent years (Table 1). Galbois and coworkers, 
in a retrospective analysis on 68 cirrhotic patients admitted 
to ICU with sepsis (31 with refractory ascites), reported 
no difference in mortality between patients receiving or 
not receiving NSBBs (5). Similarly, Robins and coworkers 
reported, in a retrospective study with 114 patients with 
ascites undergoing regular paracentesis, no significant 
difference in survival between patients using propranolol 
(mean total daily dose of 40–80 mg daily) and controls (6). 
Comparable results were reported in 61 cirrhotic patients, 
in need of paracentesis twice yearly or more frequently in 
spite of diuretic treatment, with no difference in mortality 
between patients assuming or not assuming NSBBs (7). 
Leithead and coworkers also performed a single-centre 
retrospective study on 322 patients with ascites waiting 
for liver transplantation and found that NSBBs were not 
detrimental but associated with a lower mortality. Even in 
the subgroup of patients with refractory ascites (n=117), 
NSBB remained independently associated with a lower 
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rate of death (adjusted HR =0.35; 95% CI, 0.14–0.86; 
P=0.022) (8).
Based on these findings, clinicians are continuously 
facing the need to evaluate pros and cons on the use of 
NSBBs in patients with advanced cirrhosis. In fact, while 
on the one hand the NSBBs represent a crucial option for 
primary and secondary prophylaxis of variceal bleeding, 
on the other hand caution has been suggested as they 
may reduce the cardiac response to the hyperdynamic 
circulation, leading to cardiac dysfunction and further 
deterioration in decompensated cirrhotic patients (9,10).
The Baveno VI international consensus conference 
held in 2015 recommended that, in patients with cirrhosis 
and refractory ascites, NSBBs should be used cautiously 
with close monitoring of blood pressure, serum sodium, 
and serum creatinine. In particular, NSBBs should be 
reduced/discontinued if a patient with refractory ascites 
develops systolic blood pressure <90 mmHg, hyponatremia 
<130 mEq/L or acute kidney injury (AKI). Re-initiation 
of NSBB should be considered after these abnormal 
parameters return to baseline values or after resolution of 
the precipitant; in such case, dose should be re-titrated, 
starting at the lowest dose. The consensus also underlined 
the need to reassess the risks/benefits ratio of NSBB 
periodically in each patient, as contraindications, such as 
hypotension, may be absent when the therapy is initiated 
but may eventually appear later (11). The AASLD 2016 
clinical guidelines provide similar recommendations, adding 
the suggestion of avoiding doses of more than 160mg in the 
case of propranolol or 80 mg when using nadolol in patients 
with refractory ascites and spontaneous bacterial peritonitis 
(SBP) (12).
In patients with advanced cirrhosis, development of 
AKI represents an important landmark in the disease 
progression (13). When an organic kidney disease is not 
the cause of AKI, hyperdynamic circulation and cardiac 
dysfunction are the main determinants of renal impairment 
in cirrhotic patients, which may eventually progress to 
hepatorenal syndrome. Even in presence of a pre-existent 
chronic kidney disease, hemodynamic deterioration may 
contribute to further worsening kidney function.
Kim et al. (14) performed a nested case-control study 
from a cohort of patients listed for liver transplantation, 
aimed at evaluating the association between NSBBs 
treatment and the development of AKI. They analyzed 
410 patients, cases were patients with AKI (205 patients) 
and controls were matched patients, based on MELD-Na, 
age, baseline creatinine and duration of follow-up, who 
did not develop AKI. The unadjusted proportional hazard 
regression analysis for predicting the development of AKI, 
showed that non-Caucasian race, high MELD and MELD-
Na scores at baseline, and ascites were associated with an 
increased risk of AKI. To investigate further the influence 
of ascites and of the use of NSBBs the patients were divided 
into 4 subgroups: in patients with ascites the use of NSBB 
increased the risk of AKI approximately 3-folds (HR =3.31; 
95% CI, 1.57–6.95; P<0.01); whereas, in patients without 
ascites, NSBB reduced the risk of AKI by approximately 
5-fold (HR =0.19; 95% CI, 0.06–0.60; P<0.01). These 
results need to be considered with interest, as those of 
other observational studies. On one side, NSBBs seem to 
favor the development of AKI in patients with cirrhosis and 
ascites, on the other side NSBBs seem to protect from AKI 
patients with cirrhosis and without ascites. 
These findings seem to support the “window hypothesis” 
which proposed that NSBBs improve survival in cirrhosis 
only during a certain “window” of the disease (8): not too 
early, when the adrenergic system is not yet activated in the 
initial stages of cirrhosis, and not too late, when a number 
of circulatory changes occur for an adaptive response to the 
peripheral vasodilation, effective hypovolemia, and arterial 
hypotension. At this advanced stage, the effects of NSBBs 
in reducing blood pressure and cardiac output may result 
in decreased survival in a subset of patients (12). The study 
by Kim suggests that even the presence of ascites can be a 
risk factor for the use of NSBBs. However, as patients with 
ascites were not excluded from the old trials considering 
NSBBs for the primary and secondary prevention of 
variceal bleeding in cirrhotic patients, and shared the same 
beneficial effects of the therapy with beta-blockers, these 
results are difficult to be interpreted. Although the authors 
tried to overcome the limitations of an observational 
retrospective design by planning a nested case-control 
study, many problems could still have influenced the results. 
A relevant limitation of the study is due to the fact that the 
use of NSBBs could be a marker of more advanced cirrhosis 
even in patients with ascites, identifying those with more 
severe portal hypertension, and multivariable analysis has 
limited power to account for all potential confounders. 
It is not reported whether patients with ascites, receiving 
and not receiving NSBBs, were comparable for MELD, 
MELD-Na and hemodynamic parameters. Moreover, being 
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a retrospective study, as also stated by the authors, it was 
not possible to assess accurately the severity of ascites, and 
this may represent an important bias in a study in which 
the conclusions involve the presence or absence of ascites. 
Another important point to take into account is that, in 
cirrhotic patients, AKI can have different causes (organic 
and functional AKI) and these may also affect the influence 
of multiple factors which may act as confounders. Detailed 
information about AKI is also lacking.
In conclusion, prospective RCT would be needed on 
the use of NSBBs in decompensated cirrhotic patients with 
ascites however these trials are difficult to organize and 
will need a large sample size. A case control study could be 
useful if the two groups were patients matched for MELD, 
MELD Na, creatinine, mean arterial pressure, with the 
same type of ascites (refractory, recurrent, severe) taking or 
not taking NSBBs. The better and more relevant end point 
should probably be survival.
In the meanwhile, the Baveno recommendations 
can be utilized in clinical practice to remind that severe 
hypotension is a well-known contraindication for NSBBs 
which may suggest dose reduction or even therapy 
discontinuation.
Last but not least, NSBBs may have several beneficial 
effects in patients with cirrhosis beyond the reduction in 
portal hypertension. They reduce markers of intestinal 
permeability, bacterial translocation and systemic 
inflammation, and also the risk of SBP (15,16). The risk to 
enlarge the indication to stop NSBBs in cirrhotic patients 
without a real evidence could be as to “throw the baby out 
with the bath water”.
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